Specifically, promoter DNA hypermethylation, one of the most common mechanisms implicated in the silencing of CDKN2A in tumours, was not found to account for this, confirming the work of others who reported that only one of 15 chordoma cases tested had definitive evidence of CDKN2A promoter methylation 6. The gene discussed is CDKN2A; the disease is neoplasm.